.webp&w=3840&q=75)
BeOne announces 4 cancer programs for ESMO 2026
- BeOne Medicines announced new data presentations covering four investigational cancer treatments at ESMO 2026, scheduled for October 23–27 in Madrid.
- BeOne shares closed at US$369.06 on October 16, down 1.34%, before the announcement.
- The company will also present seven TEVIMBRA abstracts covering lung and gastrointestinal cancers, including Phase 3 findings involving ZIIHERA.
BeOne Medicines (NASDAQ:ONC) announced presentations covering four investigational cancer therapies and seven TEVIMBRA abstracts at ESMO 2026 in Madrid.
The presentations follow earlier 2026 clinical disclosures, including Phase 1 findings for BGB-B2033 and BGB-43395 at major oncology conferences.
The program includes BGB-B2033 for liver cancer, BG-C477 and BGB-58067 for selected advanced tumors, and BGB-43395 for breast cancer.
BeOne expects the October 23–27 congress to provide additional clinical evidence.
Seven TEVIMBRA abstracts include Phase 3 HERIZON-GEA-01 data evaluating treatment with ZIIHERA and chemotherapy for HER2-positive gastroesophageal cancer.
Earlier in 2026, BeOne reported Phase 3 HERIZON-GEA-01 survival findings, advanced its CDK4 inhibitor development and disclosed additional investigational gastrointestinal cancer data.
Frequently asked questions
More from United States
Anthropic prices IPO above range at $83, sources say
Palo Alto Networks revenue advances to $3.44 billion, up 39%
Woodward records 22% sales growth in fiscal 2026 as revenue hits $4.4B
C3is reports $1.2 million Q3 net loss as revenue rises
Cosmos Health revenue hits $53.6 million, up 17.6%
Summit launches Phase III lung cancer trial for ivonescimab



